High Constitutive Signaling of the Ghrelin Receptor - Identification of a Potent Inverse Agonist

Molecular Endocrinology

Volumn 17, Issue 11, 2003, Pages 2201-2210

  Holst, Birgitte ^a,b,d   Cygankiewicz, Adam ^a   Jensen, Tine Halkjær ^a   Ankersen, Michael ^c   Schwartz, Thue W ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b 7TM Pharma A S   (Denmark)

^c NOVO NORDISK A S   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APPETITE STIMULANT; GHRELIN; GHRELIN RECEPTOR; GHRELIN RECEPTOR STIMULATING AGENT; HORMONE ANTAGONIST; HORMONE RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; INOSITOL PHOSPHATE; MOTILIN; MOTILIN RECEPTOR; SUBSTANCE P [1 DEXTRO ARGININE 5 DEXTRO PHENYLALANINE 7,9 DEXTRO TRYPTOPHAN 11 LEUCINE]; SUBSTANCE P DERIVATIVE; UNCLASSIFIED DRUG;

AGONIST; ANIMAL CELL; APPETITE; ARTICLE; CELL STRAIN 293; CELL STRAIN COS7; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GROWTH HORMONE RELEASE; HUMAN; HUMAN CELL; INVERSE AGONIST; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; HUMANS; INOSITOL PHOSPHATES; LIGANDS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; OBESITY; PEPTIDE HORMONES; PHOSPHOLIPASE C; RECEPTORS, G-PROTEIN-COUPLED; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0242330291     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2003-0069     Document Type: Article

References (47)

1. Bowers CY, Momany F, Reynolds GA, Chang D, Hong A, Chang K 1980 Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology 106:663-667
2. Bowers CY, Momany FA, Reynolds GA, Hong A 1984 On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114:1537-1545
3. Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G, 1995 Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci USA 92:7001-7005
4. Smith RG, Cheng K, Schoen WR, Pong SS, Hickey G, Jacks T, Butler B, Chan WW, Chaung LY, Judith F, 1993 A nonpeptidyl growth hormone secretagogue. Science 260:1640-1643
5. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJ, Dean DC, Melillo DG, Van Der Ploeg LH, 1996 A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273:974-977
6. Smith RG, Van Der Ploeg LH, Howard AD, Feighner SD, Cheng K, Hickey GJ, Wyvratt Jr MJ, Fisher MH, Nargund RP, Patchett AA 1997 Peptidomimetic regulation of growth hormone secretion. Endocr Rev 18:621-645
7. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K 1999 Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660
8. Hosoda H, Kojima M, Mizushima T, Shimizu S, Kangawa K 2002 Structural divergence of human ghrelin; identification of multiple ghrelin-derived molecules produced by post-translational processing. J Biol Chem 278:64-70
9. Bednarek MA, Feighner SD, Pong SS, McKee KK, Hreniuk DL, Silva MV, Warren VA, Howard AD, Van Der Ploeg LH, Heck JV 2000 Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem 43:4370-4376
10. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, Korbonits M 2002 The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87:2988
11. Tschop M, Smiley DL, Heiman ML 2000 Ghrelin induces adiposity in rodents. Nature 407:908-913
12. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S 2001 A role for ghrelin in the central regulation of feeding. Nature 409:194-198
13. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS 2001 A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50:1714-1719
14. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ 2002 Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623-1630
15. Horvath TL, Diano S, Sotonyi P, Heiman M, Tschop M 2001 Minireview: ghrelin and the regulation of energy balance - a hypothalamic perspective. Endocrinology 142:4163-4169
16. Kojima M, Hosoda H, Matsuo H, Kangawa K 2001 Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 12:118-122
17. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG 2000 Central nervous system control of food intake. Nature 404:661-671
18. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, Nakazato M 2002 The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123:1120-1128
19. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA, Kasuga M 2001 Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120:337-345
20. Itoh Z 1997 Motilin and clinical application. Peptides 18:593-608
21. Rosenkilde MM, Kledal TN, Brauner-Osborne H, Schwartz TW 1999 Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J Biol Chem 274:956-961
22. Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS, Asch AS, Cesarman E, Gershengorn MC, Mesri EA, Gerhengorn MC 1998 G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391:86-89
23. Hansen BS, Raun K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, Lau J, Andersen PH, Ankersen M 1999 Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol 141:180-189
24. McKee KK, Palyha OC, Feighner SD, Hreniuk DL, Tan CP, Phillips MS, Smith RG, Van Der Ploeg LH, Howard AD 1997 Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol Endocrinol 11:415-423
25. Pomes A, Pong SS, Schaeffer JM 1996 Solubilization and characterization of a growth hormone secretagogue receptor from porcine anterior pituitary membranes. Biochem Biophys Res Commun 225:939-945
26. Holst B, Hastrup H, Raffetseder U, Martini L, Schwartz TW 2001 Two active molecular phenotypes of the tachykinin NK1 receptor revealed by G-protein fusions and mutagenesis. J Biol Chem 276:19793-19799
27. Rosenkilde MM, Cahir M, Gether U, Hjorth SA, Schwartz TW 1994 Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding. J Biol Chem 269:28160-28164
28. Ahuja SK, Murphy PM 1996 The CXC chemokines growth-regulated oncogene (GRO) α, GROβ, GROγ, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem 271:30545-20550
29. Cheng K, Chan WW, Butler B, Wei L, Smith RG 1993 A novel non-peptidyl growth hormone secretagogue. Horm Res 40:109-115
30. Elling CE, Nielsen SM, Schwartz TW 1995 Conversion of antagonist-binding site to metal-ion site in the tachykinin Nk-1 receptor. Nature 374:74-77
31. Elling CE, Thirstrup K, Holst B, Schwartz TW 1999 Conversion of agonist site to metal-ion chelator site in the β(2)-adrenergic receptor. Proc Natl Acad Sci USA 96:12322-12327
32. Chen W, Shields TS, Stork PJ, Cone RD 1995 A colorimetric assay for measuring activation of Gs-and Gq-coupled signaling pathways. Anal Biochem 226:349-354
33. Matthews RP, Guthrie CR, Wailes LM, Zhao X, Means AR, McKnight GS 1994 Calcium/calmodulin-dependent protein kinase types II and IV differentially regulate CREB-dependent gene expression. Mol Cell Biol 14:6107-6116
34. Cervia D, Petrucci C, Bluet-Pajot MT, Epelbaum J, Bagnoli P 2002 Inhibitory control of growth hormone secretion by somatostatin in rat pituitary GC cells: sst(2) but not sst(1) receptors are coupled to inhibition of single-cell intracellular free calcium concentrations. Neuroendocrinology 76:99-110
35. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K 2001 Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50:227-232
36. Shimizu-Albergine M, Ippolito DL, Beavo JA 2001 Down-regulation of fasting-induced cAMP response element-mediated gene induction by leptin in neuropeptide Y neurons of the arcuate nucleus. J Neurosci 21:1238-1246
37. Nijenhuis WA, Oosterom J, Adan RA 2001 AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol Endocrinol 15:164-171
38. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS 1997 Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278:135-138
39. Ollmann MM, Barsh GS 1999 Down-regulation of melanocortin receptor signaling mediated by the amino terminus of Agouti protein in Xenopus melanophores. J Biol Chem 274:15837-15846
40. Woll PJ, Rozengurt E 1988 [D-Arg1,D-Phe5,D-Trp7,9,Leu11] substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc Natl Acad Sci USA 85:1859-1863
41. Fincham CI, Higginbottom M, Hill DR, Horwell DC, O'Toole JC, Ratcliffe GS, Rees DC, Roberts E 1992 Amide bond replacements incorporated into CCK-B selective "dipeptoids." J Med Chem 35:1472-1484
42. Horwell DC 1996 Use of the chemical structure of peptides as the starting point to design nonpeptide agonists and antagonists at peptide receptors: examples with cholecystokinin and tachykinins. Bioorg Med Chem 4:1573-1576
43. Schwartz MW, Morton GJ 2002 Obesity: keeping hunger at bay. Nature 418:595-597
44. Feighner SD, Howard AD, Prendergast K, Palyha OC, Hreniuk DL, Nargund R, Underwood D, Tata JR, Dean DC, Tan CP, McKee KK, Woods JW, Patchett AA, Smith RG, Van Der Ploeg LH 1998 Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. Mol Endocrinol 12:137-145
45. Richard F, Barroso S, Martinez J, Labbe-Jullie C, Kitabgi P 2001 Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2. Mol Pharmacol 60:1392-1398
46. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR 1989 Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-68
47. Gether U, Johansen TE, Schwartz TW 1993 Chimeric NK1 (substance P) NK3 (neurokinin B) Receptors. J Biol Chem 268:7893-7898